Get the Stockscreener App
1.91
6.83%
-0.14
After Hours:
2.00
0.09
+4.71%
22nd Century Group, Inc. stock is traded at $1.91, with a volume of 78,431.
It is down -6.83% in the last 24 hours and down -50.84% over the past month.
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
See More
Previous Close:
$2.05
Open:
$2.08
24h Volume:
78,431
Relative Volume:
2.10
Market Cap:
$1.38M
Revenue:
$17.59M
Net Income/Loss:
$-13.12M
P/E Ratio:
-0.00886
EPS:
-215.5494
Net Cash Flow:
$-8.60M
1W Performance:
-10.75%
1M Performance:
-50.84%
6M Performance:
-91.78%
1Y Performance:
-84.64%
1-Day Range:
$1.9056
$2.14
1-Week Range:
$1.75
$2.15
52-Week Range:
$1.66
$168.00
22nd Century Group, Inc. Stock (XXII) Company Profile
Name
22nd Century Group, Inc.
Sector
Industry
Phone
716-270-1523
Address
8560 Main Street, Williamsville, NY
Compare XXII vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XXII
22nd Century Group, Inc.
|
1.91 | 1.48M | 17.59M | -13.12M | -8.60M | -215.55 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
22nd Century Group, Inc. Stock (XXII) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-22 | Initiated | Alliance Global Partners | Buy |
| Jun-15-22 | Initiated | Craig Hallum | Buy |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Jul-23-21 | Initiated | Cowen | Outperform |
| Oct-16-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-11-16 | Reiterated | Chardan Capital Markets | Buy |
View All
22nd Century Group, Inc. Stock (XXII) Latest News
22nd Century Group misses Q4 top-line estimates - MSN
XXII SEC Filings22Nd Century 10-K, 10-Q, 8-K Forms - Stock Titan
Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN
Form 8-KCurrent report - ADVFN
Form S-3Registration statement under Securities Act of 1933 - ADVFN
22nd Century Group Reports First Quarter 2025 Financial Results - ADVFN
[EFFECT] 22nd Century Group, Inc. SEC Filing - Stock Titan
22nd Century Group (NASDAQ: XXII) registers $250M shelf for multiple securities - Stock Titan
22nd Century Group (NASDAQ: XXII) files $1.84M at‑the‑market shelf - Stock Titan
Does 22nd Century Group Inc outperform in volatile markets - baoquankhu1.vn
XXII Forecast, Price Target & Analyst Ratings | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
22nd Century Group's reduced nicotine bet falls flat with investors - MSN
22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative - ADVFN
XXII: 22nd Century Progresses with Low-Nicotine Cigarette Develo - GuruFocus
22nd Century to File New PMTA for 100mm VLN - Tobacco Reporter
22nd Century Group's reduced nicotine bet falls flat with investors (XXII:NASDAQ) - Seeking Alpha
Only FDA-authorized low-nicotine cigarette maker targets 100mm format - Stock Titan
US Market Wrap: What are the future prospects of 22nd Century Group Inc2026 Closing Moves & Reliable Price Breakout Signals - baoquankhu1.vn
Death Cross: Does 22nd Century Group Inc outperform in volatile marketsMarket Volume Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
XXII PE Ratio & Valuation, Is XXII Overvalued - Intellectia AI
XXII Technical Analysis | Trend, Signals & Chart Patterns | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
XXII Should I Buy - Intellectia AI
22nd Century (XXII) registers $250M shelf; Needham ATM up to $1.84M - Stock Titan
Income Plays: Is ARDT stock a buy or sellTrade Signal Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Jobs Data: What are the future prospects of 22nd Century Group Inc2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn
Will 22nd Century Group Inc outperform tech stocksWeekly Stock Recap & Low Volatility Stock Suggestions - baoquankhu1.vn
22nd Century Group Achieves Debt-Free Status to Fuel Growth Strategy - AD HOC NEWS
XXII (22nd Century Group) Debt-to-EBITDA : -0.15 (As of Dec. 2025) - GuruFocus
22nd Century finished fiscal 2025 with smaller loss, low volume of very-low-nicotine cigarette sales - Winston-Salem Journal
22nd Century Group Reports Q4 and Full Year 2025 Results: VLN® Expansion, Higher Margins, and Debt-Free Growth - Minichart
Tag: EBITDA - Tobacco Reporter
22nd Century Group Inc (XXII) Q4 2025 Earnings Call Highlights: Strategic Shift Fuels Growth Amidst Challenges - gurufocus.com
22nd Century Group Inc (XXII) Q4 2025 Earnings Call Highlights: Strategic Shift Fuels Growth ... By GuruFocus - Investing.com Canada
22nd Century Group, Inc. 2025 Annual Report: VLN Reduced Nicotine Cigarettes, Risks, and Business Overview - Minichart
22nd Century Debt-Free in Announcing 2025 Results - Tobacco Reporter
22nd Century Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Earnings call transcript: 22nd Century Group’s Q4 2025 shows strategic shift - Investing.com Australia
XXII: Transitioned to growth in 2025, launching VLN products and strengthening financials - TradingView — Track All Markets
XXII Reports Q4 Revenue Decline with Strategic Adjustments in Fo - GuruFocus
22nd Century Group (XXII) Reports Q4 Revenue Decline and Misses Estimates - GuruFocus
22nd Century Group reports Q4 revenue $3.5M, exits 2025 debt-free with $7.1M cash - TradingView
22nd Century (NASDAQ: XXII) 2025 revenue drops to $17.6M as mix shifts - Stock Titan
22nd Century Group reports $17.59M revenue and $(71.26) EPS; narrower net loss - TradingView
22nd Century Group Q4 losses narrow on market expansion, improved margins - TradingView
Going concern risk and VLN nicotine strategy at 22nd Century (NASDAQ: XXII) - Stock Titan
22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
22nd Century Group Inc (XXII) Q4 2025: Everything You Need To Kn - GuruFocus
XXII Q4'25 Earnings: EPS estimate is (2.10) USD - TradingView
22nd Century Group, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
22nd Century (XXII) files registration for 33.87M underlying shares from Series B deal - Stock Titan
22nd Century Group Inc expected to post a loss of $7.35 a shareEarnings Preview - TradingView
22nd Century Group, Inc. Stock (XXII) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):